HOLLISTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Sidoti Small Cap Virtual Conference on September 18th, 2024, with a presentation time of 9:15 am ET.
The presentation will be webcast live and can be accessed through the investor relations section of the Harvard Bioscience website: https://investor.harvardbioscience.com/events-and-presentations. A replay will be available on the company’s website shortly after the presentation has concluded.
To schedule a one-on-one meeting, please contact the conference organizers directly.
About Harvard Bioscience, Inc.
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world. For more information, please visit our website at www.harvardbioscience.com
Company Contact:
Harvard Bioscience
Jen Cote, Chief Financial Officer
(508) 893-3120
Investor Contacts:
Three Part Advisors
Sandy Martin / Erol Girgin / William Shelmire
This email address is being protected from spambots. You need JavaScript enabled to view it.
(214) 616-2207
| Last Trade: | US$2.11 |
| Daily Change: | 0.01 0.48 |
| Daily Volume: | 278,332 |
| Market Cap: | US$92.040M |
November 07, 2024 October 03, 2024 September 18, 2024 June 06, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
